贝伐珠单抗联合化疗方案对转移性结直肠癌疗效及EGFR表达的影响
|
摘要
目的探讨贝伐珠单抗联合化疗方案对转移性结直肠癌疗效及表皮生长因子受体(EGFR)的影响。方法选取2016年6月至2018年6月本院收治的转移性结直肠癌患者120例,随机分为研究组和对照组,每组60例。对照组使用经典FOLFOX方案进行化疗,研究组在此基础上联合贝伐珠单抗治疗,两组均治疗4个周期。比较治疗前后两组患者的疗效和EGFR水平。结果治疗4个周期后,研究组总有效率为53.33%,明显高于对照组的33.33%,差异有统计学意义(P<0.05);治疗4个周期后,两组患者EGFR水平[(4.81±1.53)mg/L]均明显低于治疗前[(18.05±2.72)mg/L],且研究组患者EGFR水平明显低于对照组[(6.24±1.29)mg/L],差异均有统计学意义(均P<0.05)。两组患者治疗期间白细胞减少、血小板减少、蛋白尿、消化道不良反应、肝功能异常、周围神经毒性发生率比较差异均无统计学意义(均P>0.05)。结论贝伐珠单抗可有效提升转移性结直肠癌患者FOLFOX化疗方案的治疗效果,安全性较佳。
Objective To investigate the effect of bevacizumab combined with chemotherapy on the expression of epidermal growth factor receptor(EGFR) in metastatic colorectal cancer.Methods 120 patients with metastatic colorectal cancer admitted to our hospital from June 2016 to June 2018 were randomly divided into study group and control group with 60 cases in each group. The control group was treated with classical FOLFOX regimen, and the study group was treated with bevacizumab for 4 cycles. The curative effect and the level of EGFR were compared between the two groups before and after treatment. Results After 4 cycles of treatment, the total effective rate of the study group(53.33%)was significantly higher than that of the control group(33.33%), with statistical significance(P<0.05); After 4 cycles of treatment, the levels of EGFR in the two groups [(4.81±1.53)mg/L]were significantly lower than those before treatment[(18.05±2.72)mg/L], and the level of EGFR in the study group [(6.24±1.29)mg/L]was significantly lower than that in the control group(P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups during treatment(P>0.05).Conclusion Bevacizumab can effectively improve the efficacy of FOLFOX chemotherapy in patients with metastatic colorectal cancer, and its safety is better.
Objective To investigate the effect of bevacizumab combined with chemotherapy on the expression of epidermal growth factor receptor(EGFR) in metastatic colorectal cancer.Methods 120 patients with metastatic colorectal cancer admitted to our hospital from June 2016 to June 2018 were randomly divided into study group and control group with 60 cases in each group. The control group was treated with classical FOLFOX regimen, and the study group was treated with bevacizumab for 4 cycles. The curative effect and the level of EGFR were compared between the two groups before and after treatment. Results After 4 cycles of treatment, the total effective rate of the study group(53.33%)was significantly higher than that of the control group(33.33%), with statistical significance(P<0.05); After 4 cycles of treatment, the levels of EGFR in the two groups [(4.81±1.53)mg/L]were significantly lower than those before treatment[(18.05±2.72)mg/L], and the level of EGFR in the study group [(6.24±1.29)mg/L]was significantly lower than that in the control group(P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups during treatment(P>0.05).Conclusion Bevacizumab can effectively improve the efficacy of FOLFOX chemotherapy in patients with metastatic colorectal cancer, and its safety is better.
引文
[1] 丘嘉煌,李燕,李科,等.广州市2004-2013年结直肠癌发病趋势分析[J].广东医学, 2016,37(22):3334-3337.
[2] 李道娟,梁迪,靳晶,等.河北省40年结直肠癌发病和死亡分析[J].中国癌症杂志, 2017,27(3):212-218.
[3] 湛玉东,历春,盖晓东.协同共刺激分子B7-H4与消化道肿瘤关系研究进展[J].北华大学学报(自然科学版),2017,18(3):348-351.
[4] 郑树,张苏展,黄彦钦,等.结直肠癌研究30年回顾和现状[J].实用肿瘤杂志,2016, 31(1):2-5.
[5] Padman S,Padbury R,Beeke C, et al. Liver only metastatic disease in patients with metastatic colorectal cancer: impact of surgery and chemotherapy[J].Acta Oncologica, 2013,52(8):1699-1706.
[6] 吴鸿伟,邓薇,姚宏伟,等.梗阻性结直肠癌临床病理特征及预后分析[J].中华消化外科杂志,2018,17(2):148-153.
[7] 许可,陈国江,彭晖,等.结直肠癌靶向治疗耐药机制的研究进展[J].国际药学研究杂志,2017,44(5):402-408.
[8] 夏秀娟,李粉婷,刘佳,等.转移性结直肠癌抗血管生成靶向治疗的研究进展[J].现代生物医学进展,2016,16(1):187-191.
[9] 陈福敏,罗君,杜茂福,等.血清CEA、CA19-9水平变化与结直肠癌患者术前TNM分期的关联性[J].中国卫生工程学,2018,17(3):419-421.
[2] 李道娟,梁迪,靳晶,等.河北省40年结直肠癌发病和死亡分析[J].中国癌症杂志, 2017,27(3):212-218.
[3] 湛玉东,历春,盖晓东.协同共刺激分子B7-H4与消化道肿瘤关系研究进展[J].北华大学学报(自然科学版),2017,18(3):348-351.
[4] 郑树,张苏展,黄彦钦,等.结直肠癌研究30年回顾和现状[J].实用肿瘤杂志,2016, 31(1):2-5.
[5] Padman S,Padbury R,Beeke C, et al. Liver only metastatic disease in patients with metastatic colorectal cancer: impact of surgery and chemotherapy[J].Acta Oncologica, 2013,52(8):1699-1706.
[6] 吴鸿伟,邓薇,姚宏伟,等.梗阻性结直肠癌临床病理特征及预后分析[J].中华消化外科杂志,2018,17(2):148-153.
[7] 许可,陈国江,彭晖,等.结直肠癌靶向治疗耐药机制的研究进展[J].国际药学研究杂志,2017,44(5):402-408.
[8] 夏秀娟,李粉婷,刘佳,等.转移性结直肠癌抗血管生成靶向治疗的研究进展[J].现代生物医学进展,2016,16(1):187-191.
[9] 陈福敏,罗君,杜茂福,等.血清CEA、CA19-9水平变化与结直肠癌患者术前TNM分期的关联性[J].中国卫生工程学,2018,17(3):419-421.